Mon.Jan 02, 2023

article thumbnail

Promising RSV Vaccine Candidate Raises Hopes

Pharmacy Times

Pharmacists should educate patients about managing respiratory syncytial virus and let them know they may soon be able to get vaccinated.

Vaccines 149
article thumbnail

Convenience an Important Factor in the Multiple Myeloma Treatment Equation

Drug Topics

The COVID-19 pandemic revealed the advantages of treatment that involved fewer in-person office visits, according to recent research.

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Immunizing Older Individuals Requires Flexibility, Nuance

Pharmacy Times

When it comes to vaccination efforts, remember that patients 65 years or older are not a homogeneous group.

article thumbnail

Best of Women's Health Coverage

Drug Topics

Take a look back at our most popular women's health coverage for 2022.

98
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Biden signs $1.7T omnibus, paving way for multiple health policy priorities

Fierce Healthcare

Biden signs $1.7T omnibus, paving way for multiple health policy priorities. pminemyer. Mon, 01/02/2023 - 22:24.

96
article thumbnail

Acasti, seeking to expand use of old steroid, posts clinical data on oral spray in rare disease

Fierce Pharma

Acasti, seeking to expand use of old steroid, posts clinical data on oral spray in rare disease. ntaylor. Tue, 01/03/2023 - 01:49.

82

More Trending

article thumbnail

Alteogen signs global license deal with Sandoz

Pharmaceutical Technology

South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology. Under the terms of the agreement, Sandoz will have the global rights to use Alteogen’s novel hyaluronidase, ALT-B4, for the development and commercialisation of a subcutaneous version of a biosimilar product.

52
article thumbnail

A Message From Alex January 2023

Oswald's

January 1st, 2023 marks the beginning of my third year running the ol’ family pharmacy here in Naperville. I’m grateful for our wonderful team (pictured on the right) that continues to care for our community in our 148th year of business. Thanks to our Operations Manager Karen for creating the wonderful collage of our team… The post A Message From Alex January 2023 appeared first on Oswald's Pharmacy.

52
article thumbnail

China NMPA recommends priority review for Everest’s IgA nephropathy therapy

Pharmaceutical Technology

The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has recommended priority review for Everest Medicines’ new drug application (NDA) of Nefecon to treat primary immunoglobulin A nephropathy (IgAN). The regulatory support for the accelerated approval of Nefecon is to treat IgAN in adult patients who are at risk of rapid disease progression.

52
article thumbnail

Computational Analysis of HCV Entry Inhibitors for Hepatitis C Treatment – A Molecular Docking Approach

Pharma Tutor

Computational Analysis of HCV Entry Inhibitors for Hepatitis C Treatment – A Molecular Docking Approach. admin. Mon, 01/02/2023 - 20:35. About Author: Karthika M. Postgraduate in Bioinformatics. Bharathiar University m.karthika1@gmail.com.

55
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Mayo spreads support to InSitu with prolonged-release cancer drug co-development pact

Fierce Pharma

Mayo spreads support to InSitu with prolonged-release cancer drug co-development pact. ntaylor. Tue, 01/03/2023 - 01:53.

52
article thumbnail

As BI-1361849 moves closer to clinical approval, what is the likelihood that the drug will be approved?

Pharmaceutical Technology

BI-1361849 is under clinical development by Boehringer Ingelheim International and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

article thumbnail

Driving ESG through 2023’s Economic Headwinds

Pharmaceutical Commerce

A Q&A with AstraZeneca’s Country President for Belgium & Luxembourg, Keira Driansky.

52
article thumbnail

Danicamtiv, what is the likelihood that the drug will be approved?

Pharmaceutical Technology

Danicamtiv is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

January 2023 Promotions

Oswald's

The post January 2023 Promotions appeared first on Oswald's Pharmacy.

52
article thumbnail

Lifirafenib maleate, what is the likelihood that the drug will be approved?

Pharmaceutical Technology

Lifirafenib maleate is under clinical development by BeiGene and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

article thumbnail

How Can You Prepare for the Internal Medicine Board Exam?

Board Vitals - Pharmacist

The Internal Medicine Board Certification Exam is the final step for doctors looking to specialize in Internal Medicine. This in-depth exam covers a range of different topics, including Hematology, Psychiatry, and Dermatology. Passing the boards is not a guarantee, but with the right plan in place, you will be confident and prepared come test day. What is the Internal Medicine Board Exam?